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 This is a suggested vaccination schedule that is based on 
the science of immunology and the art of inducing immuniza-
tion through administrating vaccines or bacterins. This fact 
sheet will not cite data or give references. However, for recent 
thorough discussions on immunization, readers should refer 
to articles by Drs. Roth, Ellis, Cullor, Schultz, Hutcheson, and 
West in the 26th Annual Proceedings of the AABP Meeting 
September 16-19, 1993, pages 3-39.
 First, some definitions or descriptions of types of immunity 
need to be discussed.
 1. Native defense mechanisms. These mechanisms are 
functional immediately when an infectious agent enters 
the body even if the animal has not been immunized. 
They include many things such as enzymes, tears, sa-
liva, white blood cells, stomach acids, and many other 
factors that may kill bacteria or viruses. They are most 
effective when an animal has been properly immunized, 
and some animals genetically have better native defense 
mechanisms.
 2. Passive immunity. This is a temporary immunity and 
comes from some source other than being made by the 
animal. The most common and most important kind of 
passive immunity is the antibodies that newborn animals 
receive through the mother’s colostrum. These immuni-
ties have finite lives that vary among diseases. In cattle, 
blackleg colostral antibodies are gone by about two 
months of age, while BVD colostral antibodies may last 
six months or longer. Other examples of passive immunity 
are tetanus antitoxin, which animals or people are given 
when exposed, and gama globulin, which people are given 
when exposed to hepatitis “A.” An animal cannot develop 
permanent or acquired immunity through vaccination if 
passive antibodies are present.
 3. Acquired immunity. This is permanent or semi-permanent 
immunity that is developed by the animal’s immune system 
when the animal is exposed to a disease or properly vac-
cinated. It takes at least one week and usually two weeks 
following infection or vaccination for the immune system 
to produce the antibodies that are necessary for protec-
tion. The antibodies produced are specific against that 
particular organism or disease, unlike the native defense 
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mechnaisms, which may destroy many different organ-
isms. There are three types of acquired immunity.
a.	 Humoral	immunity.	This is immunity from anitbodies 
that are produced by lymphocytes (white blood cells). 
These antibodies are circulating in the bloodstream 
and can attach to the specific infectious agent to 
inactivate or neutralize the organism so it can be 
destroyed or removed by some of the native defense 
mechanisms. These antibodies are most commonly 
present in colostral antibodies. Some organisms are 
resistant to humoral antibodies and must be controlled 
by cell mediated immunity or secretory immunity.
 b.	Cell	mediated	 immunity. Cell mediated immunity is 
produced by other types of lymphocytes when an 
animal is exposed or properly vaccinated. These lym-
phocytes specially recognize the disease organism, 
and when later exposed, they attack and inactivate 
the infectious organism. Cell mediated immunity is 
important in control of respiratory diseases. Cell medi-
ated immunity is not as easily produced as humoral 
immunity and is rarely produced by a killed vaccine 
because the infectious agent usually has to replicate 
in animal cells to stimulate this system. This is why 
modified	live	vaccines	(MLVs) are produced.
 c.	 Mucosal	 or	 secretory	 immunity. The antibodies re-
sponsible for humoral and cell mediated immunity 
are circulating in the blood stream. It is difficult for 
these to get to the linings of the intestinal tract, mam-
mary gland, respiratory tract, and reproductive tract; 
therefore, they are not as effective against infections 
of those organs. Secretory immunity is best produced 
by the cells lining the organ following natural infection. 
MLVs are effective if they attack the lining cells of the 
organ that produces the secretory antibodies. If the 
MLV can be introduced into the organ, the organ will 
develop secretory antibodies. This is what occurs, 
for example, following vaccination of calves with the 
intranasal IBR-PI3 vaccine (Infectious Bovine Rhino-
tracheitis and Parainfluenza-3 viruses).
 4. Vaccination. The process of inoculating a vaccine into 
an animal. Does not imply an immune response has oc-
curred.
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 5. Immunization. The process of vaccinating an animal, 
which responds with a detectable immune response. 
(Does not imply that the animal is protected from the 
disease.)
 6. Endemic. A disease that is always present in an area or 
herd. (i.e., blackleg, anaplasmosis, and others in certain 
areas).
 Vaccination failures may occur for a number of reasons, 
including animal factors, vaccine factors, and human error. 
Examples are (1) colostral antibodies in young animals pre-
venting development of acquired immunity; (2) improper stor-
age, handling, or injection of vaccines; (3) animals incubating 
or highly stressed at time of vaccination; (4) overwhelming 
infection too great for vaccine immunity to provide protection; 
and (5) too much time between initial injection and booster 
injection of killed vaccines. There are many other factors that, 
along with the above factors, are actually related to proper 
planning and design of the vaccination program.
 Dr. Schultz, in the 1993 AABP proceedings, lists the 
objectives	of	immunization:
 1. Immunization should produce a good humoral, cellular, 
and local immune response similar to natural infection.
 2. Immunization should produce protection against clinical 
disease and reinfection.
 3. Immunization should give protection over several years, 
preferably a lifetime.
 4. Immunization should result in minimal immediate side 
reactions (e.g., reduced milk production, weight loss, 
infection of the fetus with abortion, congenital anomalies, 
or persistent infections).
 5. The vaccine should be simple to administer in a form 
acceptable to the producer and practitioner.
 6. Cost and benefits of administration of vaccine should 
clearly outweigh the cost and risk of natural disease.
 Obviously, not all vaccines will meet all the above ob-
jectives all of the time. Some cannot be given to pregnant 
animals, some require booster vaccinations, many do not 
impart longtime immunity, and some are not cost-effective. 
Therefore, when selecting a vaccination program, one must 
do a risk assessment to determine the desired vaccines and 
the time to administer the vaccines. What is the probability of 
the animals in question becoming clinically or subclinically ill? 
If they are susceptible to infection, will the morbidity, mortal-
ity, cost of treatment, and loss of production be sufficiently 
reduced to warrant the cost of vaccines and labor involved? 
Remember, vaccines do not induce a 100 percent immune 
response and not all immune responses are protective against 
disease. The selection of a vaccine is also part science and 
part art. Science enters into the equation when veterinarians 
keep up with the data on immune responses and side effects 
from newer vaccines. Also important is management and/or 
nutritional information that enhances an immunization program. 
Art is the application of the known science to a particular situ-
ation, herd, or environment.
 Recent scientific and lay literature has been laden with 
information on respiratory disease and vaccination programs 
for prevention and control of respiratory diseases. The plethora 
of lay information (and some veterinary articles) have fed the 
controversy of what kind of vaccine to use and how often to 
administer the vaccine. Much misinformation and fear has 
resulted from relying too much on the art of vaccination rather 
than the science of immunology. For the cow-calf producer, it 
certainly has detracted from the concept of herd immunity.
 Good cow-calf herd immunity has classically been thought 
of as preventing clostridial diseases, abortion diseases, calf 
scours, and respiratory diseases in replacements, or, if the 
Table 1. Facts to Remember about MLV and NI Vaccines.
	 	 Killed-Inactivated
Modified	Live	Vaccines	(MLVs)	 Non-Infectious	Vaccines
1. Provide longer duration and more complete immunity 1. Provide short-lived, systemic immunity.
 than non-infectious vaccines.
2. Should produce cellular and secretory immunity. 2. Provide poor cellular and secretory immunity.
3. Do not require multiple vaccinations for  3. Often require re-vaccination to ensure immunologic
 immunologic memory.  memory.
4. Often do not require re-vaccinating or require 4. Require multiple vaccinations for active immunity.
 fewer re-vaccinations during life of an animal.
5. Rarely cause hypersensitivities, but may be virulent 5. Often cause hypersensitivity reactions.
 for certain individual animals or may cause animals to
 revert to virulence.
6. When used on pregnant animals, some abortions will occur 6. Cannot cause disease even in immunologically 
   compromised animal.
producer retained ownership, respiratory diseases in stocker 
and feeder cattle. Little attention has been given to the effect 
of cow-calf vaccination programs on the next link of the beef 
food chain. In line with the Beef Quality Assurance and Food 
Safety programs, cow-calf veterinarians and cow-calf produc-
ers should also start addressing herd immunity as to how it 
affects food safety (injection site lesions) and feedlot health 
(morbidity and antibiotic residues). 
 One of the most important considerations in 
designing a vaccination program, after the specific 
vaccines have been selected, is timing. When should 
the vaccine be administered? Incorrect timing of 
vaccination is the greatest cause for vaccines failing 
to immunize. Timing includes such considerations 
as: 1) the effects of maternal (colostral) antibody on 
active immunization; 2) the period of time between 
injection of vaccines that require multiple doses; 3) 
the age the disease most often occurs; and 4) the 
competence of the immune system, especially as it 
may be affected by age and stress.
With the above thoughts in mind, the following programs for 
different herd scenarios are suggested:
 A. The first and most simple is for a cow herd that is known 
to have immunity (through exposure or vaccination) to the 
common viral and bacterial disease seen in Oklahoma. In 
such a herd, outbreaks ordinarily would not be expected, 
and the goal would be to maintain herd immunity (active 
in yearlings and cows and maternal passive immunity in 
nursing calves).
  The only vaccines considered imperative in this program 
are the Clostridial bacterin/toxoids and the IBR-BVD MLVs. 
These diseases are endemic, and all Oklahoma herds will 
be exposed at one time or another. With transportation of 
infected and incubating cattle being what it is, an unvac-
cinated closed herd that is protected by quarantine is a 
myth. These vaccines are highly effective and inexpensive 
when used as recommended.
 1. At approximately two months of age, all calves should 
be vaccinated for clostridial diseases with an effective 
bacterin/toxoid, making sure products and methods will 
be used that provide immunity and minimize injection 
site reations. Calves this age (and sometimes younger) 
have lost passive protection for clostridial diseases 
and are therefore susceptible to infection. Calves this 
age in herds with good maternal immunity will not 
likely be susceptible to other common diseases. The 
passive immunity to BVD will still be at high enough 
levels to interfere with injectable vaccines and may 
still be protective. Colostral passive immunity to IBR, 
PI3, and Leptospirosis are intermediate in duration and 
may or may not be protective. If these diseases are 
a threat in young nursing calves, nasal IBR-PI3 vac-
cine and Leptospira bacterin may be used. However, 
the clostridium antigens are the only ones routinely 
recommended.
 2. At two to four weeks before weaning, the following 
are recommended:
 a.	 The	Clostridium	bacterin/toxoid	of	choice. In most 
herds, no further clostridial vaccinations will be 
necessary; however, some herds may require 
annual boosters.
 b.	 IBR,	PI3,	and	BVD	MLVs.	Five-way Leptospira 
bacterin may be incorporated if it is considered 
necessary in your area. Remember, this herd is 
known to have immunity to these viruses, and 
administering a MLV to calves is not threaten-
ing to pregnant dams the calves are nursing. 
This vaccine is known to provide the quickest 
and highest humoral response, plus it produces 
cellular and secretory antibodies. (CAUTION: At 
weaning, some calves may still have passive BVD 
immunity which could block active immunity.)
	 c.	 A	Pasteurella	leukotoxoid	vaccine, which should 
be boostered in two to four weeks (weaning). Data 
show that such a program significantly reduces 
respiratory disease and treatment time of respora-
tory disease after weaning in exposed calves.
 d.	 Calfhood	vaccination	of	replacement	heifers	with	
strain	19	Brucella abortus	vaccine. Vaccination 
has protected our clean herds and I do not rec-
ommend discontinuing this vaccine until we have 
maintained a Free State status.
 3. At weaning, a booster for the Pasteurella leukotoxoid 
vaccination is recommended. Some veterinarians 
recommend boosters of IBR, BVD, and PI3 MLVs, 
but most revaccinations with a MLV product do not 
stimulate a secondary response. The advantage of 
this booster would be if a previously inhibitave pas-
sive immunity had waned, thereby permitting the MLV 
antigens to stimulate a primary response.
 4. At one year of age, the following vaccines are recom-
mended for replacements:
 a.	 IBR-BVD	MLVs	with	a		5-way	Leptospria	bacterin	as	
a	diluent.	This vaccination should provide lifelong 
immunity against IBR-BVD infections. There will 
likely be no secondary response if the weaning 
vaccination provided immunization, but this admin-
istration is important to permanently protect those 
that still had BVD passive immunity at weaning. 
This is important for protecting the embryo and fetus 
plus providing colostral antibodies. The Leptospria 
immunity is short-lived and must be boostered at 
least annually.
	 b.	 Campylobacter	 (vibriosis)	 bacterin. If Campylo-
bacter infertility is a possibility, the first injection of 
the bacterin should be administered and reinjected 
in two to four weeks. This bacterin must be boost-
ered annually. Remember, camplylobacterosis is 
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primarily an infertility disease, so breeding animals 
must be protected during the early part of the breed-
ing season. These bacterins provide short-lived 
immunity and do not have maximum protective 
titers at breeding when given in combination with 
Leptospria bacterin at pregancy palpation or when 
the calf is weaned. To be most effective, Campylo-
bacter bacterins should be given prebreeding.
 5. At weaning or pregnancy testing time, cows should 
receive annual boosters of the following:
 a.	 Five-way	Leptospria	bacterin.	Cowherd Leptospria 
infections primarily involve late term abortions, and 
best protection is provided when the bacterin is 
administered at pregnancy testing time. Herds with 
a high degree of exposure to Leptospira abortion 
may require twice-a-year vaccination.
 6. Cow herd vaccination is necessary for stimulation of 
maternal (colostral) antibodies against calf scours. K-
99 E.	coli bacterins administered at least four weeks 
before calving have been shown to be effective in re-
ducing colibaclosis of newborn calves when	adequate 
colostrum is consumed within	six	to	twelve	hours of 
birth. The first year (pregnant replacement heifers) 
of vaccination must include two injections two to four 
weeks apart. The second injection should be given at 
least four before calving. Annual boosters are given 
four to eight weeks before calving. Some companies 
include rota and corona virus vaccines in their products. 
Studies of antibody levels in colostrum and newborn 
calves following adequate nursing indicate that cur-
rently available rota-corona vaccines do not stimulate 
adequate maternal antibody production to be protec-
tive for the calf. However, the K-99 E.	coli	bacterins 
are protective and are recommended for herds with 
colibacillosis infections. Some companies claim their 
products stimulate high and long-lasting antibody titers 
so well that the vaccine can be administered to the cow 
at weaning time, thereby eliminating another handling 
event. Question your supplier closely regarding this 
claim.
 B. Many cow-calf herds do not have herd vaccination 
programs, or herd immunity is unknown. Also, some 
herds calve all year around, and vaccinations cannot be 
performed uniformly at “working time,” “weaning time,” 
“before breeding,” etc. In some of these herds, a vaccina-
tion program is finally initiated when a severe respiratory 
disease outbreak or an abortion storm occurs. In these 
herds, the use of modified live viral vaccines is probably 
too risky to females in different stages of pregnancy. The 
administration of MLVs to naive pregnant females runs a 
high risk of fetal infection and abortion. In these cases, herd 
immunity must be established through the administration 
of killed or chemically inactived MLVs that are safe for 
pregnant females. Remember, all such products must be 
administered twice two to four weeks apart. One injection 
will not provide protection and if the injections are given 
less than two weeks or greater than four weeks after the 
first injection, immunity will be significantly decreased or 
perhaps non existent. These protocols must be followed 
precisely. The chemically altered modified live IBR PI3 
and killed BVD products are preferred over killed. All cattle 
(cows and calves) are given these vaccines to establish 
herd immunity. However, to maintain herd immunity with 
the same products, they must be reinjected on an annual 
basis because the killed or chemically inactivated MLVs 
do not impart permanent immunity, and cellular immunity 
is poor.
  If such a herd has a defined calving season/seasons, 
herd immunity can be initiated as prescribed above. 
Continue herd immunity with MLVs as follows:
1. Two to four weeks before weaning, vaccinate calves 
with the clostridial bacterin/toxoid and the Pasteurella 
leukotoxoid. Do not use the IBR, BVD. PI3 MLV 
because the dams may be susceptible due to de-
creaseing immunity from previous killed or inactivated 
vaccines.
2. At weaning, booster the calves with the Pasteurella 
leukotoxoid and give the IBR, BVD, PI3 MLV. This 
starts these calves towards herd immunity as in knows 
immune herd in “A” above.
3. After the cows have calved but at least 30 days before 
breeding, give the IBR, BVD, PI3 MLV to cows and 
replacement heifers. Within two weeks, this herd will 
have good permanent herd immunity, and herd vac-
cination is continued as noted in “A” above.
 Some producers cannot or choose not to have a de-
fined calving seasons and cannot feel secure using the 
modified viral products with there is risk of accidental 
injection in pregnant cows. For these producers, the 
recommended “Keep it Simple” procedure is to use 
a killed or chemically inactivated modified live virus 
in all cattle annually. To establish herd immunity, all 
replacements must be vaccinated with these products 
twice, two to four weeks apart in the first year.
C. Respiratory disease is becoming more common in 
nursing beef calves. In the ’90s, more cases of Pas-
teurella pneumonia have been diagnosed in nursing 
beef calves (two to four months of age). Occasionally, 
IBR virus has also been isolated, but not as frequently 
as Pasteurella species. The suggested approach to 
these has been to use the following vaccines.
1. Intranasal	 IBR,	PI3.	Local mucosal immunity is 
quickly established, and interferon is produced 
within 24-48 hours, which is somewhat effective 
against all viruses for a short time.
2. Pasteurella	leukotoxoid. This should be reinjected 
in two weeks for good immunity, although two 
products (One-Shot® and Presponse®) now have 
labels claiming “one shot” effectiveness.
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Maternal antibodies for IBR, PI3, and pasteurella 
are greatly diminished by six to eight weeks of age, 
making these calves susceptible when exposed to 
sufficient numbers or especially virulent organisms. In 
these cases, the above vaccines should be immuniz-
ing and could be administered at six to eight weeks 
of age on an annual basis in susceptible herds. The 
preweaning or weaning vaccinations should be used 
as in “A” above, except the pasteurella needs to be 
given only once.
D. Other vaccines. In some areas, Hemophilus	somnus 
bacterin and Bovine Respiratory Syncitial Virus (BRSV) 
MLVs are recommended.
1. The data indicate that Hemophilus bacterins do 
not significantly reduce respiratory disease but 
may reduce the prevalence of thromboembolic 
meningoencephalitis (TEME). One should question 
the cost effectiveness of incorporating Hemophilus 
bacterin in most herds.
2. The inclusion of BRSV vaccine may be helpful in 
endemic areas, but its use it not recommended 
unless the virus has been identified as a causative 
factor of respiratory disease. This vaccine must be 
injected twice two to four weeks apart to stimulate 
immunity and adds a significant cost to the IBR, 
BVD, PI3 combination. This organism is not com-
monly isolated in Oklahoma, and it may not play 
an important part in respiratory disease here.
3. Until 1995, the only anaplasmosis vaccine available 
was Ft. Dodge’s Anaplaz®, and all veterinarians 
are aware of Neonatal Isoerytholysis (NI) that is 
caused by incompatible blood type antigens that 
may be in the vaccine. NI is caused by certain blood 
type antibodies that may be present in the cow’s 
colostrum and which cause lysis of the calves’ 
red blood cells and often death after consuming 
colostrum. Many veterinarians and producers have 
been reluctant to use the vaccine. Approximately 
10 years ago, the company was able to identify 
the blood type determinant that stimulated the 
production of the offending antibodies. Therefore, 
vaccine is not produced from blood with these blood 
types. The occurrence of NI is now quite rare and 
has not been reported in Oklahoma in the last 10 
years. Anaplaz® is quite safe and effective when 
used according to directions.
 A new vaccine, Plasvax® from Mallindrodt, was 
introduced in 1995. It has no danger of NI and can 
be administered at any stage of reproduction. This 
vaccine has been shown to protect against several 
strains of anaplasma, and it is hoped that Plasvax® 
will prove to be as protective as Anaplaz®.
 In anaplasmosis endemic areas, vaccination is 
recommended as the most cost-effective means 
of control. Vaccines will not prevent cattle from 
becoming infected and will not prevent cattle from 
becoming carriers, but will prevent clinical disease 
and loss of production. Remember, vaccinated 
animals will test positive on blood tests and may 
prevent their interstate movement.
Summary
I. Herds with a good immune program
	 A.	Calves
  1. Two months of age
   a. Clostridial bacterin
    2-way or 4-way
   b. IBR-PI3 nasal vaccine if necessary
   c. 5-way Leptospira bacterin if necessary
   d. Pasteurella leukotoxoid if necessary
  2. 2 to 4 weeks before weaning
   a. Booster clostridial
   b. Modified live IBR-PI3-BVD vaccine
   c. Pasteurella leukotoxoid
   d. Brucella strain 19—heifers
  3. Weaning
   a. Booster Pasteurella leukotoxoid
	 B.	Yearling	Replacements
  1. Booster MLV-IBR, BVD vaccine
  2. Optional 
   a. 5-way Leptospira bacterin
   b. Campylobacter fetus venerealis for vibrio
	 C.	Adult	Cows—annually
  1. Weaning/pregnancy testing
   a. 5-way Lepto
  2. Precalving for calf scours
   a. E. coli K-99
    First year—2 doses
    Many contain roto-corono virus vaccine also
  3. Prebreeding
   a. Campylobacter fetus venerealis for vibrio if 
    necessary
	 D.	Special	vaccines
  1. Hemophilus somnus bacterin
   a. Not very effective
   b. Use only if necessary
  2. Anaplasmosis vaccine
   a. Effective control in endemic areas
   b. Follow label instructions
  3. Bovine Respiratory Syncytial Virus (BRSV)
   a. May be helpbul in infected herds, but not 
    reported much in Oklahoma
   b. Follow label instructions




  1. IBR-BVD
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   a. Vaccinate all cattle weaning age or older with 
    killed or chemically altered IBR-PI3-BVD 
    vaccine.
   b. Yearling replacements
    (1) Modified live IBR-BVD vaccine
    (2) 5-way Leptospira bacterin
   c. Cows after calving but more than 30 days 
    before breeding
    (1) Modified live IBR-BVD
   d. Weaning calves
    (1)  Modified live IBR-PI3-BVD
 The above vaccinations can be completed in approxi-
mately 12 months after starting program and can not be 
continued as a program for the immune herd as in (I A-D) 
above.   
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The Oklahoma Cooperative Extension Service 
Bringing the University to You!
• It provides practical, problem-oriented education 
for people of all ages.  It is designated to take 
the knowledge of the university to those persons 
who do not or cannot participate in the formal 
classroom instruction of the university.
• It utilizes research from university, government, 
and other sources to help people make their own 
decisions.
• More than a million volunteers help multiply the 
impact of the Extension professional staff.
• It dispenses no funds to the public.
• It is not a regulatory agency, but it does inform 
people of regulations and of their options in meet-
ing them.
• Local programs are developed and carried out in 
full recognition of national problems and goals.
• The Extension staff educates people through 
personal contacts, meetings, demonstrations, 
and the mass media.
• Extension has the built-in flexibility to adjust its 
programs and subject matter to meet new needs. 
Activities shift from year to year as citizen groups 
and Extension workers close to the problems 
advise changes.
The Cooperative Extension Service is the largest, 
most successful informal educational organization 
in the world. It is a nationwide system funded and 
guided by a partnership of federal, state, and local 
governments that delivers information to help people 
help themselves through the land-grant university 
system.
Extension carries out programs in the broad catego-
ries of  agriculture, natural resources and environment; 
family and consumer sciences; 4-H and other youth; 
and community resource development. Extension 
staff members live and work among the people they 
serve to help stimulate and educate Americans to 
plan ahead and cope with their problems.
Some characteristics of the Cooperative Extension 
system are:
•  The federal, state, and local governments 
cooperatively share in its financial support and 
program direction.
• It is administered by the land-grant university as 
designated by the state legislature through an 
Extension director.
• Extension programs are nonpolitical, objective, 
and research-based information.
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